Attention Deficit Disorder With Hyperactivity, Autistic Disorder
Conditions
Brief summary
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
(most important): * ASD (autistic disorder or Asperger's disorder or Pervasive Developmental Disorder - Not Otherwise Specified \[PDD NOS\]) * Criteria A through D for Attention-Deficit/Hyperactivity Disorder (ADHD) * At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale-IV-Parent Version * Intelligence quotient (IQ) score \> 60
Exclusion criteria
(most important): * weight under 20 kg * Patients who meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) criteria for ASD other than Autistic Disorder, PDD-NOS or Asperger's Disorder;history of Bipolar I or II disorder, schizophrenia, another psychotic disorder, substance abuse;Have a significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, or seizure disorder identified by history, physical examination, or laboratory tests; Patients who have taken (or are currently taking) anticonvulsants for seizure control. * patients at serious suicidal risk. * Contraindication to the use of atomoxetine * Patients who in the investigator's judgment are likely to need psychotropic medications apart from the drug. Patients who at any time during Study Period II are likely to begin a structured psychotherapy, likely to require hospitalization (i.e. in-patient treatment) or likely to be dismissed from in-patient treatment. Psychotherapy (including hospitalization) initiated at least 2 months prior to study participation is acceptable; however, after study participation has begun, only during Study Period III supportive or educational therapy is permitted.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score | Baseline and 8 weeks | Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders, Version IV (DSM-IV) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Baseline, 8 weeks, 28 weeks | A 28-item rating scale (0 \[not at all/never\] to 3 \[very much true/very often\]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index. |
| ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score | 28 weeks | Measures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54. |
| Sleep Measure Scale | Baseline, 8 weeks, 28 weeks | 10-item parent-based scale assessing sleep problems (6 point Likert scale). Scores: Difficulty falling asleep (1-6); Quality of sleep (3-18); Functional outcome (6-36). Lower scores indicate higher problems with item. Open-ended items: Time to fall asleep (1 \[0-15 minutes\] to 5 \[\>1 hour\]); Total hours (numbers associated with hours of sleep). |
| Aberrant Behavior Checklist (ABC) | Baseline, 8 weeks, 28 weeks | The ABC is a 58-item informant-based scale comprised of five subscales (Irritability \[15 items\], Lethargy \[16\], Stereotypic Behaviors \[7\], Hyperactivity \[16\], Inappropriate Speech \[4\]). Individual item scores range from 0 (no problem) to 3 (severe problem). Subscale scores are total of individual item scores in subscale: Irritability (0-45); Lethargy (0-48); Stereotypic (0-21); Hyperactivity (0-48); Inappropriate Speech (0-12). |
| Children's Social Behavior Questionnaire (CSBQ) Total Score | Baseline, 8 weeks, 28 weeks | CSBQ is filled out by parents and consists of 49 items. Items are rated in an ordinal rather than a discrete fashion in order to establish the extent to which problems are present. The CSBQ consists of six subscales. Individual item scores range from 0=does not apply to 2=applies clearly. Total score ranges from 0 to 98. |
| General Health Questionnaire (GHQ) Total Score | Baseline, 8 weeks, 28 weeks | Parental distress is measured with the GHQ. The raw total score (based on 0-0-1-1 scoring system) can be used as an overall index of psychological distress, ranging from 0 to 12 with higher scores indicating more distress. |
| Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | Baseline, 8 weeks, 28 weeks | The NOSI contains 123 items to be completed by the primary caregiver. Individual item scores range from 1 (completely agree) to 6 (completely disagree). Total scores range from 123 to 738. |
| Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Baseline, 8 Weeks | Focused attention assessed distractibility. Child needs to identify a specific target (eg, Cherry); non-target is any other fruit. Child presses yes when target occurs in relevant position (eg, one of vertical positions on diamond). Child presses no when target is absent, or when target appears on horizontal position (irrelevant target). Error rates are percentage of missing relevant targets and percentage of false alarms in response to (irr)relevant (non)targets based on number of errors/total number of trials X 100. |
| Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Baseline, 8 Weeks | Task is the same as described in Outcome Measure #10. Reaction times (RT) for hits are mean RTs of correct responses to relevant targets. RTs for correct rejections are mean RTs for correct rejections are mean RTs for correct no responses to irrelevant targets and relevant nontargets. |
| Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I) | 8 weeks, 28 weeks | Measures total improvement (or worsening) of a patient's ADHD symptoms from the beginning of treatment (1=very much improved, 7=very much worsened). |
| Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Baseline, 8 Weeks | The memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to identify (e.g., an animal). A yes is required whenever the target is part of the displayed set of four stimuli (all animals). Load 2 has 2 targets. Whenever 1 of the targets appears in the successively displayed sets of four animals, a yes is required. Targets are present in 50% of trials. Error rates are the percentages of errors made in each task condition, based on the number of errors/total number of trials X 100. |
| Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Baseline, 8 Weeks | Memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to remember (one animal). A yes is required whenever the target is part of displayed set of 4 animals. Load 2 has 2 animals. A yes is required whenever one of the animals appears in successively displayed sets of 4 animals. Targets are present in 50% of the trials. Reaction time (RT) for hits is mean RT of correct yes responses to targets. RT correct rejections are mean RTs of correct no responses when target was missing. |
| Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Baseline, 8 weeks | Task is the same as described in Outcome Measure #14. Standard deviations of reaction times (RT) assess intraindividual variability in RT referring to the two conditions creating hits and correct rejections as mentioned in Outcome Measure #14. |
| Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy | Baseline, 8 weeks | A complex visuo-motor flexibility task that aims at measuring eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Accuracy is the mean distance between the mouse cursor and the moving target. |
| Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement | Baseline, 8 weeks | A complex visuo-motor flexibility task that measures eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Stability is within subject variability of mean distance between cursor and target. |
| Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Baseline, 8 weeks | Measures inhibition of pre-potent responses. 24 Go signals (open squares) are presented, randomly mixed with 24 No-Go signals (closed squares). Subjects are required to press a key if a Go signal (target) appears on the screen but to withhold a response if they see a No-Go signal. Error rate is the percentage of key presses to No-Go signals/total number of trials X 100. |
| Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Baseline, 8 weeks | Measures ability to neglect stimuli interfering with predefined stimulus-response coupling. Child presented with displays of 9 colored squares. Child responds to color of central square by pressing left mouse key when blue, and right mouse key when yellow. Part 1 (40 trials), surrounding squares may be same color (compatible) or different (neutral). Part 2 (80 trials), in 50% of trials, surrounding squares have color corresponding to predefined key press for other hand (incompatible). Error rates are percentages of errors in response to compatible and incompatible signals, respectively. |
| Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Baseline, 8 weeks | Task is the same as described in Outcome Measure #19. Mean reaction times (RTs) are computed for correct responses to compatible and incompatible flankers, respectively. |
| Cytochrome P450 2D6 Genotype | baseline | Genotype characterization was used to determine participants' metabolic status. |
| Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Baseline, 8 Weeks | Task is the same as described in Outcome Measure #10. Standard deviations of reaction times (RT) assess intraindividual variability in RT and refer to the same conditions as those for mean reaction times described in Outcome Measure #11. |
Countries
Netherlands
Participant flow
Pre-assignment details
Study Period I was a screening and wash-out period. Study Period II (visits 2-6) was an 8-week double-blind period. Patients were randomized at Visit 2. Study Period III (visits 6-11) was a 20-week open-label extension period. Treatment groups in Study Period III refer to treatment group assignment during Double-Blind Period.
Participants by arm
| Arm | Count |
|---|---|
| Atomoxetine atomoxetine: 0.5 mg/kg/day daily (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks. | 48 |
| Placebo placebo: daily (QD), by mouth (PO) for 8 weeks.
Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks. | 49 |
| Total | 97 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Study Period II - Double Blind | Adverse Event | 1 | 0 |
| Study Period II - Double Blind | Lack of Efficacy | 1 | 0 |
| Study Period II - Double Blind | Parent/Caregiver Decision | 1 | 0 |
| Study Period II - Double Blind | Physician Decision | 0 | 1 |
| Study Period II - Double Blind | Protocol Violation | 2 | 2 |
| Study Period II - Double Blind | Withdrawal by Subject | 0 | 0 |
| Study Period III - Open Label | Adverse Event | 5 | 3 |
| Study Period III - Open Label | Lack of Efficacy | 0 | 4 |
| Study Period III - Open Label | Parent/Caregiver Decision | 1 | 1 |
| Study Period III - Open Label | Physician Decision | 0 | 3 |
| Study Period III - Open Label | Protocol Violation | 0 | 0 |
| Study Period III - Open Label | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Atomoxetine | Total | Placebo |
|---|---|---|---|
| Age Continuous | 9.9 years STANDARD_DEVIATION 2.72 | 9.9 years STANDARD_DEVIATION 2.8 | 10.0 years STANDARD_DEVIATION 2.9 |
| Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version- Total Score | 40.7 units on a scale STANDARD_DEVIATION 7.47 | 39.6 units on a scale STANDARD_DEVIATION 8 | 38.6 units on a scale STANDARD_DEVIATION 8.43 |
| Autism Diagnostic Interview-Revised (ADI-R) | 37.4 units on a scale STANDARD_DEVIATION 12.45 | 37.3 units on a scale STANDARD_DEVIATION 11.09 | 37.2 units on a scale STANDARD_DEVIATION 9.68 |
| Body Mass Index | 18.5 kilogram/meter squared STANDARD_DEVIATION 3.4 | 18.3 kilogram/meter squared STANDARD_DEVIATION 3.37 | 18.1 kilogram/meter squared STANDARD_DEVIATION 3.36 |
| Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale | 5.0 units on a scale STANDARD_DEVIATION 0.74 | 5.1 units on a scale STANDARD_DEVIATION 0.83 | 5.1 units on a scale STANDARD_DEVIATION 0.9 |
| Height | 146.0 centimeters STANDARD_DEVIATION 16.57 | 147.0 centimeters STANDARD_DEVIATION 17.84 | 148.0 centimeters STANDARD_DEVIATION 19.11 |
| Race/Ethnicity African | 0 participants | 1 participants | 1 participants |
| Race/Ethnicity Caucasian | 48 participants | 95 participants | 47 participants |
| Race/Ethnicity Hispanic | 0 participants | 1 participants | 1 participants |
| Region of Enrollment Netherlands | 48 participants | 97 participants | 49 participants |
| Score for Performance IQ | 89.9 units on a scale STANDARD_DEVIATION 16.59 | 92.4 units on a scale STANDARD_DEVIATION 17.14 | 94.9 units on a scale STANDARD_DEVIATION 17.46 |
| Score for the Overall Scale Intelligence | 91.0 units on a scale STANDARD_DEVIATION 16.41 | 92.9 units on a scale STANDARD_DEVIATION 17.08 | 94.6 units on a scale STANDARD_DEVIATION 17.71 |
| Score for Verbal IQ | 93.2 units on a scale STANDARD_DEVIATION 18.49 | 93.8 units on a scale STANDARD_DEVIATION 18.29 | 94.4 units on a scale STANDARD_DEVIATION 18.26 |
| Sex: Female, Male Female | 6 Participants | 14 Participants | 8 Participants |
| Sex: Female, Male Male | 42 Participants | 83 Participants | 41 Participants |
| Weight | 41.0 kilograms STANDARD_DEVIATION 14.92 | 41.2 kilograms STANDARD_DEVIATION 15.46 | 41.5 kilograms STANDARD_DEVIATION 16.12 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 39 / 48 | 32 / 49 |
| serious Total, serious adverse events | 0 / 48 | 0 / 49 |
Outcome results
ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score
Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders, Version IV (DSM-IV) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.
Time frame: Baseline and 8 weeks
Population: Number of randomized participants with a value at baseline and 8 week endpoint. Last Observation Carried Forward analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score | Baseline Total Score (n=48, n=49) | 40.7 units on a scale | Standard Deviation 7.47 |
| Atomoxetine | ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score | 8 Week Endpoint Total Score (n=43, n=47) | 32.3 units on a scale | Standard Deviation 10.97 |
| Placebo | ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score | Baseline Total Score (n=48, n=49) | 38.6 units on a scale | Standard Deviation 8.43 |
| Placebo | ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score | 8 Week Endpoint Total Score (n=43, n=47) | 37.3 units on a scale | Standard Deviation 9.57 |
Aberrant Behavior Checklist (ABC)
The ABC is a 58-item informant-based scale comprised of five subscales (Irritability \[15 items\], Lethargy \[16\], Stereotypic Behaviors \[7\], Hyperactivity \[16\], Inappropriate Speech \[4\]). Individual item scores range from 0 (no problem) to 3 (severe problem). Subscale scores are total of individual item scores in subscale: Irritability (0-45); Lethargy (0-48); Stereotypic (0-21); Hyperactivity (0-48); Inappropriate Speech (0-12).
Time frame: Baseline, 8 weeks, 28 weeks
Population: Randomized participants with values at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Lethargy: 8 Week (n=43, n=46) | 11.1 units on a scale | Standard Deviation 9.34 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Stereotypic: 28 Week (n=38, n=36) | 3.3 units on a scale | Standard Deviation 4.03 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Irritiability: 8 Week (n=43, n=46) | 14.5 units on a scale | Standard Deviation 9.36 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Hyperactivity: Baseline (n=47, n=49) | 28.2 units on a scale | Standard Deviation 9.4 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Lethargy: 28 Week (n=38 , n=36) | 7.5 units on a scale | Standard Deviation 7.24 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Hyperactivity: 8 Week (n=43, n=45) | 22.5 units on a scale | Standard Deviation 11.05 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Lethargy: Baseline (n=47, n=49) | 12.7 units on a scale | Standard Deviation 8.33 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Hyperactivity: 28 Week (n=38, n=36) | 16.4 units on a scale | Standard Deviation 12.17 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Stereotypic: Baseline (n=47, n=49) | 6.6 units on a scale | Standard Deviation 5.07 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Inappropriate Speech: Baseline (n=47, n=49) | 4.8 units on a scale | Standard Deviation 3.21 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Irritiability: 28 Week (n=38, n=36) | 11.5 units on a scale | Standard Deviation 10.12 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Inappropriate Speech: 8 Week (n=43, n=46) | 3.8 units on a scale | Standard Deviation 2.92 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Stereotypic: 8 Week (n=43, n=46) | 3.6 units on a scale | Standard Deviation 4.01 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Inappropriate Speech: 28 Week (n=38, n=36) | 3.1 units on a scale | Standard Deviation 3.22 |
| Atomoxetine | Aberrant Behavior Checklist (ABC) | Irritiability: Baseline (n=47, n=49) | 17.4 units on a scale | Standard Deviation 9.15 |
| Placebo | Aberrant Behavior Checklist (ABC) | Inappropriate Speech: 28 Week (n=38, n=36) | 2.9 units on a scale | Standard Deviation 2.35 |
| Placebo | Aberrant Behavior Checklist (ABC) | Irritiability: Baseline (n=47, n=49) | 16.2 units on a scale | Standard Deviation 9.49 |
| Placebo | Aberrant Behavior Checklist (ABC) | Irritiability: 8 Week (n=43, n=46) | 15.4 units on a scale | Standard Deviation 9.8 |
| Placebo | Aberrant Behavior Checklist (ABC) | Irritiability: 28 Week (n=38, n=36) | 10.4 units on a scale | Standard Deviation 8.05 |
| Placebo | Aberrant Behavior Checklist (ABC) | Lethargy: Baseline (n=47, n=49) | 12.5 units on a scale | Standard Deviation 8.03 |
| Placebo | Aberrant Behavior Checklist (ABC) | Lethargy: 8 Week (n=43, n=46) | 11.5 units on a scale | Standard Deviation 8.17 |
| Placebo | Aberrant Behavior Checklist (ABC) | Lethargy: 28 Week (n=38 , n=36) | 8.4 units on a scale | Standard Deviation 6.64 |
| Placebo | Aberrant Behavior Checklist (ABC) | Stereotypic: Baseline (n=47, n=49) | 4.1 units on a scale | Standard Deviation 4.47 |
| Placebo | Aberrant Behavior Checklist (ABC) | Stereotypic: 8 Week (n=43, n=46) | 3.6 units on a scale | Standard Deviation 4.12 |
| Placebo | Aberrant Behavior Checklist (ABC) | Stereotypic: 28 Week (n=38, n=36) | 1.7 units on a scale | Standard Deviation 2.77 |
| Placebo | Aberrant Behavior Checklist (ABC) | Hyperactivity: Baseline (n=47, n=49) | 25.5 units on a scale | Standard Deviation 11.56 |
| Placebo | Aberrant Behavior Checklist (ABC) | Hyperactivity: 8 Week (n=43, n=45) | 24.6 units on a scale | Standard Deviation 10.33 |
| Placebo | Aberrant Behavior Checklist (ABC) | Hyperactivity: 28 Week (n=38, n=36) | 16.0 units on a scale | Standard Deviation 9.6 |
| Placebo | Aberrant Behavior Checklist (ABC) | Inappropriate Speech: Baseline (n=47, n=49) | 4.6 units on a scale | Standard Deviation 3.35 |
| Placebo | Aberrant Behavior Checklist (ABC) | Inappropriate Speech: 8 Week (n=43, n=46) | 4.5 units on a scale | Standard Deviation 3.26 |
ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score
Measures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0 to 54.
Time frame: 28 weeks
Population: Randomized participants with a value at timepoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Atomoxetine | ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score | 23.6 units on a scale | Standard Deviation 11.81 |
| Placebo | ADHD Rating Scale-IV-Parent Version: Investigator Scored Total Score | 25.9 units on a scale | Standard Deviation 10.58 |
Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates
Measures ability to neglect stimuli interfering with predefined stimulus-response coupling. Child presented with displays of 9 colored squares. Child responds to color of central square by pressing left mouse key when blue, and right mouse key when yellow. Part 1 (40 trials), surrounding squares may be same color (compatible) or different (neutral). Part 2 (80 trials), in 50% of trials, surrounding squares have color corresponding to predefined key press for other hand (incompatible). Error rates are percentages of errors in response to compatible and incompatible signals, respectively.
Time frame: Baseline, 8 weeks
Population: Number of participants with baseline and one non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Compatible Signals Baseline (n=32, n=35) | 7.7 error rate (percentages) | Standard Deviation 9.8 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Compatible Signals 8 Week (n=33, n=35) | -2.1 error rate (percentages) | Standard Deviation 8.92 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Incompatible Signals Baseline (n=32, n=35) | 8.4 error rate (percentages) | Standard Deviation 10.33 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Incompatible Signals 8 Week (n=32, n=35) | -0.4 error rate (percentages) | Standard Deviation 11.11 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Incompatible Signals 8 Week (n=32, n=35) | 0.1 error rate (percentages) | Standard Deviation 8.19 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Compatible Signals Baseline (n=32, n=35) | 8.5 error rate (percentages) | Standard Deviation 10.06 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Incompatible Signals Baseline (n=32, n=35) | 9.1 error rate (percentages) | Standard Deviation 6.62 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Error Rates | Compatible Signals 8 Week (n=33, n=35) | -1.8 error rate (percentages) | Standard Deviation 11.43 |
Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times
Task is the same as described in Outcome Measure #19. Mean reaction times (RTs) are computed for correct responses to compatible and incompatible flankers, respectively.
Time frame: Baseline, 8 weeks
Population: Number of participants with baseline and non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Compatible Flankers Part 2 Baseline (n=31,n=34) | 863.1 milliseconds | Standard Deviation 234.7 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Compatible Flankers Part 2 8 Week (n=33,n=35) | 901.1 milliseconds | Standard Deviation 350.27 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Incompatible Flankers Part 2 Baseline (n=31,n=35) | 959.4 milliseconds | Standard Deviation 295.32 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Incompatible Flankers Part 2 8 Week (n=33,n=35) | 931.9 milliseconds | Standard Deviation 347.99 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Incompatible Flankers Part 2 8 Week (n=33,n=35) | 946.2 milliseconds | Standard Deviation 419.63 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Compatible Flankers Part 2 Baseline (n=31,n=34) | 925.4 milliseconds | Standard Deviation 384.55 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Incompatible Flankers Part 2 Baseline (n=31,n=35) | 976.5 milliseconds | Standard Deviation 412.76 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Flanker Interference Task - Reaction Times | Compatible Flankers Part 2 8 Week (n=33,n=35) | 897.7 milliseconds | Standard Deviation 376.63 |
Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates
Focused attention assessed distractibility. Child needs to identify a specific target (eg, Cherry); non-target is any other fruit. Child presses yes when target occurs in relevant position (eg, one of vertical positions on diamond). Child presses no when target is absent, or when target appears on horizontal position (irrelevant target). Error rates are percentage of missing relevant targets and percentage of false alarms in response to (irr)relevant (non)targets based on number of errors/total number of trials X 100.
Time frame: Baseline, 8 Weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Irrelevant Targets Baseline (n=35, n=44) | 12.3 error rate (percentage) | Standard Deviation 13.95 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Irrelevant Targets 8 Week (n=35, n=44) | 10.0 error rate (percentage) | Standard Deviation 16.09 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Nontargets Baseline (n=35, n=44) | 5.7 error rate (percentage) | Standard Deviation 8.15 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Nontargets 8 Week (n=35, n=44) | 5.1 error rate (percentage) | Standard Deviation 9.48 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Targets Baseline (n=35, n=44) | 4.8 error rate (percentage) | Standard Deviation 5.49 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Targets 8 Week (n=35, n=44) | 7.3 error rate (percentage) | Standard Deviation 9.42 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Targets Baseline (n=35, n=44) | 6.9 error rate (percentage) | Standard Deviation 9.04 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Irrelevant Targets Baseline (n=35, n=44) | 11.8 error rate (percentage) | Standard Deviation 16.06 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Nontargets 8 Week (n=35, n=44) | 3.3 error rate (percentage) | Standard Deviation 7.04 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Irrelevant Targets 8 Week (n=35, n=44) | 13.3 error rate (percentage) | Standard Deviation 14.36 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Targets 8 Week (n=35, n=44) | 7.2 error rate (percentage) | Standard Deviation 14.47 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Error Rates | Relevant Nontargets Baseline (n=35, n=44) | 2.9 error rate (percentage) | Standard Deviation 5.97 |
Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections
Task is the same as described in Outcome Measure #10. Reaction times (RT) for hits are mean RTs of correct responses to relevant targets. RTs for correct rejections are mean RTs for correct rejections are mean RTs for correct no responses to irrelevant targets and relevant nontargets.
Time frame: Baseline, 8 Weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Irrelevant Target Baseline (n=34, n=42) | 1260.1 milliseconds | Standard Deviation 413.09 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Irrelevant Target 8 Week (n=32, n=43) | 1167.8 milliseconds | Standard Deviation 493.57 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Relevant Nontarget Baseline (n=34, n=43) | 1208.4 milliseconds | Standard Deviation 509.62 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Relevant Nontarget 8 Week (n=33, n=43) | 1165.4 milliseconds | Standard Deviation 570.35 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Mean Reaction Time Hits Baseline (n=34, n=42) | 1045.6 milliseconds | Standard Deviation 411.14 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Mean Reaction Time Hits 8 Week (n=33, n=43) | 1013.0 milliseconds | Standard Deviation 505.52 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Mean Reaction Time Hits Baseline (n=34, n=42) | 1084.4 milliseconds | Standard Deviation 518.5 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Irrelevant Target Baseline (n=34, n=42) | 1217.3 milliseconds | Standard Deviation 533.92 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Relevant Nontarget 8 Week (n=33, n=43) | 1168.9 milliseconds | Standard Deviation 569.16 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Irrelevant Target 8 Week (n=32, n=43) | 1206.0 milliseconds | Standard Deviation 547.64 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Mean Reaction Time Hits 8 Week (n=33, n=43) | 1017.7 milliseconds | Standard Deviation 475.82 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Reaction Times for Hits and Correct Rejections | Relevant Nontarget Baseline (n=34, n=43) | 1220.9 milliseconds | Standard Deviation 550.25 |
Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections
Task is the same as described in Outcome Measure #10. Standard deviations of reaction times (RT) assess intraindividual variability in RT and refer to the same conditions as those for mean reaction times described in Outcome Measure #11.
Time frame: Baseline, 8 Weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Irrelevant Target Baseline (n=33, n=39) | 421.0 milliseconds | Standard Deviation 263.84 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Irrelevant Target 8 Week (n=29, n=41) | 341.0 milliseconds | Standard Deviation 259.84 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Relevant Nontarget Baseline (n=33, n=40) | 442.2 milliseconds | Standard Deviation 374.99 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Relevant Nontarget 8 Week (n=30, n=41) | 442.6 milliseconds | Standard Deviation 413.74 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Standard Deviation Hits Baseline (n=33, n=39) | 434.3 milliseconds | Standard Deviation 302.61 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Standard Deviation Hits 8 Week (n=30, n=41) | 381.5 milliseconds | Standard Deviation 286.96 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Standard Deviation Hits Baseline (n=33, n=39) | 497.9 milliseconds | Standard Deviation 365.48 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Irrelevant Target Baseline (n=33, n=39) | 429.4 milliseconds | Standard Deviation 382.61 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Relevant Nontarget 8 Week (n=30, n=41) | 455.6 milliseconds | Standard Deviation 376.87 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Irrelevant Target 8 Week (n=29, n=41) | 431.7 milliseconds | Standard Deviation 363.62 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Standard Deviation Hits 8 Week (n=30, n=41) | 393.9 milliseconds | Standard Deviation 299.08 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Focused Attention Task - Standard Deviation of Reaction Times for Hits and Correct Rejections | Relevant Nontarget Baseline (n=33, n=40) | 565.6 milliseconds | Standard Deviation 455.54 |
Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates
Measures inhibition of pre-potent responses. 24 Go signals (open squares) are presented, randomly mixed with 24 No-Go signals (closed squares). Subjects are required to press a key if a Go signal (target) appears on the screen but to withhold a response if they see a No-Go signal. Error rate is the percentage of key presses to No-Go signals/total number of trials X 100.
Time frame: Baseline, 8 weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Absent Target Baseline | 8.0 error rate (percentage) | Standard Deviation 16.3 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Absent Target 8 Week | 4.5 error rate (percentage) | Standard Deviation 4.75 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Present Target Baseline | 2.0 error rate (percentage) | Standard Deviation 5.25 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Present Target 8 Week | 3.7 error rate (percentage) | Standard Deviation 10.01 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Present Target 8 Week | 1.9 error rate (percentage) | Standard Deviation 5.15 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Absent Target Baseline | 6.8 error rate (percentage) | Standard Deviation 8.49 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Present Target Baseline | 2.9 error rate (percentage) | Standard Deviation 6.14 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Go/No-Go Response Inhibition Task - Error Rates | Absent Target 8 Week | 9.0 error rate (percentage) | Standard Deviation 15.07 |
Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates
The memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to identify (e.g., an animal). A yes is required whenever the target is part of the displayed set of four stimuli (all animals). Load 2 has 2 targets. Whenever 1 of the targets appears in the successively displayed sets of four animals, a yes is required. Targets are present in 50% of trials. Error rates are the percentages of errors made in each task condition, based on the number of errors/total number of trials X 100.
Time frame: Baseline, 8 Weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 2 Baseline (n=33, n=35) | 2.0 error rate (percentage) | Standard Deviation 3.52 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 2 8 Week (n=34, n=35) | 4.0 error rate (percentage) | Standard Deviation 6.83 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 1 Baseline (n=34, n=35) | 5.9 error rate (percentage) | Standard Deviation 14.06 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 1 8 Week (n=34, n=35) | 5.3 error rate (percentage) | Standard Deviation 6.96 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 1 Baseline (n=34, n=35) | 6.5 error rate (percentage) | Standard Deviation 9.66 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 1 8 Week (34, n=35) | 7.6 error rate (percentage) | Standard Deviation 9.07 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 2 Baseline (n=33, n=35) | 9.5 error rate (percentage) | Standard Deviation 9.38 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 2 8 Week (n=34, n=35) | 8.7 error rate (percentage) | Standard Deviation 10.1 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 2 8 Week (n=34, n=35) | 10.1 error rate (percentage) | Standard Deviation 9.51 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 2 Baseline (n=33, n=35) | 4.4 error rate (percentage) | Standard Deviation 9.61 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 1 Baseline (n=34, n=35) | 6.6 error rate (percentage) | Standard Deviation 6.84 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 2 8 Week (n=34, n=35) | 4.3 error rate (percentage) | Standard Deviation 6.2 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 2 Baseline (n=33, n=35) | 9.7 error rate (percentage) | Standard Deviation 10.07 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 1 Baseline (n=34, n=35) | 5.1 error rate (percentage) | Standard Deviation 5.49 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Present Targets Load 1 8 Week (34, n=35) | 7.9 error rate (percentage) | Standard Deviation 10.93 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Error Rates | Absent Targets Load 1 8 Week (n=34, n=35) | 7.6 error rate (percentage) | Standard Deviation 13.25 |
Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections
Memory search task aims at measuring serial search processes to be carried out in working memory. There are 2 blocks (loads) with 40 trials each. Load 1 has 1 target to remember (one animal). A yes is required whenever the target is part of displayed set of 4 animals. Load 2 has 2 animals. A yes is required whenever one of the animals appears in successively displayed sets of 4 animals. Targets are present in 50% of the trials. Reaction time (RT) for hits is mean RT of correct yes responses to targets. RT correct rejections are mean RTs of correct no responses when target was missing.
Time frame: Baseline, 8 Weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 1 Baseline (n=33, n=35) | 1051.9 milliseconds | Standard Deviation 338.41 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 1 8 Week (n=34, n=34) | 1014.8 milliseconds | Standard Deviation 394.58 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 2 Baseline (n=32, n=34) | 1411.0 milliseconds | Standard Deviation 357.5 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 2 8 Week (n=34, n=34) | 1130.4 milliseconds | Standard Deviation 460.66 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 1 Baseline (n=33, n=35) | 932.7 milliseconds | Standard Deviation 295.14 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 1 8 Week (n=34, n=34) | 882.4 milliseconds | Standard Deviation 327.3 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 2 Baseline (n=32, n=34) | 1131.5 milliseconds | Standard Deviation 293.84 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 2 8 Week (n=34, n=34) | 1060.0 milliseconds | Standard Deviation 343.53 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 2 8 Week (n=34, n=34) | 1110.8 milliseconds | Standard Deviation 445.61 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 1 Baseline (n=33, n=35) | 1010.4 milliseconds | Standard Deviation 382.92 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 1 Baseline (n=33, n=35) | 881.7 milliseconds | Standard Deviation 304.42 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 1 8 Week (n=34, n=34) | 928.7 milliseconds | Standard Deviation 301.04 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 2 Baseline (n=32, n=34) | 1111.8 milliseconds | Standard Deviation 442.97 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 2 Baseline (n=32, n=34) | 1387.2 milliseconds | Standard Deviation 595.37 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Reaction Time Hits Load 1 8 Week (n=34, n=34) | 786.8 milliseconds | Standard Deviation 257.19 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Reaction Times for Hits and Correct Rejections | Load 2 8 Week (n=34, n=34) | 1294.2 milliseconds | Standard Deviation 552.25 |
Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections
Task is the same as described in Outcome Measure #14. Standard deviations of reaction times (RT) assess intraindividual variability in RT referring to the two conditions creating hits and correct rejections as mentioned in Outcome Measure #14.
Time frame: Baseline, 8 weeks
Population: Number of participants with baseline and a non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 1 Baseline (n=32, n=35) | 406.2 milliseconds | Standard Deviation 280.59 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 1 8 Week (n=32, n=33) | 408.2 milliseconds | Standard Deviation 342.39 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 2 Baseline (n=31, n=34) | 515.4 milliseconds | Standard Deviation 275.4 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 2 8 Week (n=32, n=33) | 544.9 milliseconds | Standard Deviation 338.26 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 1 Baseline (n=32, n=34) | 308.7 milliseconds | Standard Deviation 239.1 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 1 8 Week (n=33, n=33) | 261.6 milliseconds | Standard Deviation 231.32 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 2 Baseline (n=31, n=34) | 416.8 milliseconds | Standard Deviation 226.87 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 2 8 Week (n=32, n=33) | 380.6 milliseconds | Standard Deviation 280.36 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 2 8 Week (n=32, n=33) | 501.0 milliseconds | Standard Deviation 382.32 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 1 Baseline (n=32, n=35) | 415.0 milliseconds | Standard Deviation 324.66 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 1 Baseline (n=32, n=34) | 320.3 milliseconds | Standard Deviation 263.73 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 1 8 Week (n=32, n=33) | 353.2 milliseconds | Standard Deviation 273.16 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 2 Baseline (n=31, n=34) | 424.6 milliseconds | Standard Deviation 301.2 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 2 Baseline (n=31, n=34) | 577.4 milliseconds | Standard Deviation 340.89 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | SD Hits Load 1 8 Week (n=33, n=33) | 232.5 milliseconds | Standard Deviation 165.44 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Memory Search Task - Standard Deviation (SD) of Reaction Times for Hits and Correct Rejections | Load 2 8 Week (n=32, n=33) | 580.5 milliseconds | Standard Deviation 375.88 |
Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy
A complex visuo-motor flexibility task that aims at measuring eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Accuracy is the mean distance between the mouse cursor and the moving target.
Time frame: Baseline, 8 weeks
Population: Number of participants with baseline and non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy | Baseline (n=30,n=33) | 7.8 millimeters | Standard Deviation 5.62 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy | 8 Week (n=31,n=33) | 8.2 millimeters | Standard Deviation 6.88 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy | Baseline (n=30,n=33) | 8.1 millimeters | Standard Deviation 5.49 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Accuracy | 8 Week (n=31,n=33) | 10.1 millimeters | Standard Deviation 11.92 |
Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement
A complex visuo-motor flexibility task that measures eye-hand co-ordination and fine motor control. By moving mouse cursor, the child is required to follow as closely as possible a target that randomly moves across the PC-screen. Stability is within subject variability of mean distance between cursor and target.
Time frame: Baseline, 8 weeks
Population: Number of participants with baseline and non-missing postbaseline value at visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement | Baseline (n=30,n=33) | 7.6 millimeters | Standard Deviation 8.24 |
| Atomoxetine | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement | 8 Week (n=31,n=33) | 8.2 millimeters | Standard Deviation 8.61 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement | Baseline (n=30,n=33) | 8.2 millimeters | Standard Deviation 7.9 |
| Placebo | Amsterdam Neuropsychological Tasks (ANT): Pursuit Motor Control Task - Stability of Movement | 8 Week (n=31,n=33) | 9.4 millimeters | Standard Deviation 9.24 |
Children's Social Behavior Questionnaire (CSBQ) Total Score
CSBQ is filled out by parents and consists of 49 items. Items are rated in an ordinal rather than a discrete fashion in order to establish the extent to which problems are present. The CSBQ consists of six subscales. Individual item scores range from 0=does not apply to 2=applies clearly. Total score ranges from 0 to 98.
Time frame: Baseline, 8 weeks, 28 weeks
Population: Randomized participants with value at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Children's Social Behavior Questionnaire (CSBQ) Total Score | Baseline (n=48, n=49) | 53.6 units on a scale | Standard Deviation 14.81 |
| Atomoxetine | Children's Social Behavior Questionnaire (CSBQ) Total Score | 8 Week (n=43, n=46) | 46.1 units on a scale | Standard Deviation 15.88 |
| Atomoxetine | Children's Social Behavior Questionnaire (CSBQ) Total Score | 28 Week (n=38, n=35) | 40.4 units on a scale | Standard Deviation 19.55 |
| Placebo | Children's Social Behavior Questionnaire (CSBQ) Total Score | Baseline (n=48, n=49) | 52.4 units on a scale | Standard Deviation 15.97 |
| Placebo | Children's Social Behavior Questionnaire (CSBQ) Total Score | 8 Week (n=43, n=46) | 50.2 units on a scale | Standard Deviation 14.62 |
| Placebo | Children's Social Behavior Questionnaire (CSBQ) Total Score | 28 Week (n=38, n=35) | 43.6 units on a scale | Standard Deviation 17.26 |
Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I)
Measures total improvement (or worsening) of a patient's ADHD symptoms from the beginning of treatment (1=very much improved, 7=very much worsened).
Time frame: 8 weeks, 28 weeks
Population: Number of randomized participants with values at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I) | 8 Week Improvement Score | 3.5 units on a scale | Standard Deviation 1.08 |
| Atomoxetine | Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I) | 28 Week Improvement Score (n=39, n=35) | 2.5 units on a scale | Standard Deviation 1.14 |
| Placebo | Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I) | 8 Week Improvement Score | 3.9 units on a scale | Standard Deviation 0.96 |
| Placebo | Clinical Global Impressions-ADHD-Improvement (CGI-ADHD - I) | 28 Week Improvement Score (n=39, n=35) | 2.7 units on a scale | Standard Deviation 1.05 |
Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S)
A 28-item rating scale (0 \[not at all/never\] to 3 \[very much true/very often\]) completed by the teacher to assess problem behaviors related to ADHD. Subscale total scores range from 0 to 15 for Oppositional and Cognitive Problems, 0 to 21 for Hyperactivity, and 0 to 36 for ADHD Index.
Time frame: Baseline, 8 weeks, 28 weeks
Population: Number of randomized participants who had a value at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Oppositional: Baseline (n=42, n=44) | 4.1 units on a scale | Standard Deviation 3.54 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Oppositional: 8 Week (n=36, n=36) | 3.8 units on a scale | Standard Deviation 4.43 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Oppositional: 28 Week (n=26, n= 25) | 2.3 units on a scale | Standard Deviation 3.33 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Hyperactivity: Baseline (n=42, n=44) | 8.8 units on a scale | Standard Deviation 5.5 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Hyperactivity: 8 Week (n=36, n=36) | 7.6 units on a scale | Standard Deviation 5.54 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Hyperactivity: 28 Week (n=26, n=25) | 6.0 units on a scale | Standard Deviation 4.9 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Cognitive/Attention: Baseline (n=40, n=44) | 6.8 units on a scale | Standard Deviation 4.45 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Cognitive/Attention: 8 Week (n=34, n=36) | 6.1 units on a scale | Standard Deviation 4.56 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Cognitive/Attention: 28 Week (n=26, n=25) | 4.7 units on a scale | Standard Deviation 3.58 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | ADHD: Baseline (n=42, n=44) | 18.5 units on a scale | Standard Deviation 9.27 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | ADHD: 8 Week (n=36, n=36) | 15.8 units on a scale | Standard Deviation 9.85 |
| Atomoxetine | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | ADHD: 28 Week (n=26, n=25) | 13.5 units on a scale | Standard Deviation 8.61 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | ADHD: 8 Week (n=36, n=36) | 17.2 units on a scale | Standard Deviation 8.69 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Oppositional: Baseline (n=42, n=44) | 3.6 units on a scale | Standard Deviation 3.53 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Cognitive/Attention: Baseline (n=40, n=44) | 4.8 units on a scale | Standard Deviation 3.68 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Oppositional: 8 Week (n=36, n=36) | 3.4 units on a scale | Standard Deviation 3.35 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | ADHD: Baseline (n=42, n=44) | 18.1 units on a scale | Standard Deviation 7.49 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Oppositional: 28 Week (n=26, n= 25) | 1.4 units on a scale | Standard Deviation 1.98 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Cognitive/Attention: 8 Week (n=34, n=36) | 4.6 units on a scale | Standard Deviation 3.53 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Hyperactivity: Baseline (n=42, n=44) | 8.2 units on a scale | Standard Deviation 5.06 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | ADHD: 28 Week (n=26, n=25) | 12.5 units on a scale | Standard Deviation 5.95 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Hyperactivity: 8 Week (n=36, n=36) | 8.3 units on a scale | Standard Deviation 5.63 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Cognitive/Attention: 28 Week (n=26, n=25) | 4.6 units on a scale | Standard Deviation 3.85 |
| Placebo | Conners' Teacher Rating Scale - Revised: Short Form (CTRS-R:S) | Hyperactivity: 28 Week (n=26, n=25) | 5.2 units on a scale | Standard Deviation 4.13 |
Cytochrome P450 2D6 Genotype
Genotype characterization was used to determine participants' metabolic status.
Time frame: baseline
Population: All randomized participants.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Atomoxetine | Cytochrome P450 2D6 Genotype | Extensive Metabolizer | 28 participants |
| Atomoxetine | Cytochrome P450 2D6 Genotype | Intermediate Metabolizer | 13 participants |
| Atomoxetine | Cytochrome P450 2D6 Genotype | Poor Metabolizer | 6 participants |
| Atomoxetine | Cytochrome P450 2D6 Genotype | Missing | 1 participants |
| Placebo | Cytochrome P450 2D6 Genotype | Missing | 0 participants |
| Placebo | Cytochrome P450 2D6 Genotype | Extensive Metabolizer | 28 participants |
| Placebo | Cytochrome P450 2D6 Genotype | Poor Metabolizer | 6 participants |
| Placebo | Cytochrome P450 2D6 Genotype | Intermediate Metabolizer | 15 participants |
General Health Questionnaire (GHQ) Total Score
Parental distress is measured with the GHQ. The raw total score (based on 0-0-1-1 scoring system) can be used as an overall index of psychological distress, ranging from 0 to 12 with higher scores indicating more distress.
Time frame: Baseline, 8 weeks, 28 weeks
Population: Randomized participants with value at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | General Health Questionnaire (GHQ) Total Score | Baseline (n=48, n=49) | 2.9 units on a scale | Standard Deviation 3.45 |
| Atomoxetine | General Health Questionnaire (GHQ) Total Score | 8 Week (n=43, n=46) | 2.3 units on a scale | Standard Deviation 3.35 |
| Atomoxetine | General Health Questionnaire (GHQ) Total Score | 28 Week (n=38, n=36) | 1.7 units on a scale | Standard Deviation 2.61 |
| Placebo | General Health Questionnaire (GHQ) Total Score | Baseline (n=48, n=49) | 4.0 units on a scale | Standard Deviation 3.79 |
| Placebo | General Health Questionnaire (GHQ) Total Score | 8 Week (n=43, n=46) | 3.1 units on a scale | Standard Deviation 3.31 |
| Placebo | General Health Questionnaire (GHQ) Total Score | 28 Week (n=38, n=36) | 2.3 units on a scale | Standard Deviation 2.7 |
Nijmeegse Ouderlijke Stress Index (NOSI) Total Score
The NOSI contains 123 items to be completed by the primary caregiver. Individual item scores range from 1 (completely agree) to 6 (completely disagree). Total scores range from 123 to 738.
Time frame: Baseline, 8 weeks, 28 weeks
Population: Randomized participants with value at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | Baseline (n=42, n=44) | 368.6 units on a scale | Standard Deviation 79.22 |
| Atomoxetine | Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | 8 Week (n=38, n=39) | 350.0 units on a scale | Standard Deviation 75.07 |
| Atomoxetine | Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | 28 Week (n=35, n=34) | 325.2 units on a scale | Standard Deviation 85.76 |
| Placebo | Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | Baseline (n=42, n=44) | 379.5 units on a scale | Standard Deviation 78.74 |
| Placebo | Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | 8 Week (n=38, n=39) | 368.8 units on a scale | Standard Deviation 81.83 |
| Placebo | Nijmeegse Ouderlijke Stress Index (NOSI) Total Score | 28 Week (n=35, n=34) | 328.4 units on a scale | Standard Deviation 89.23 |
Sleep Measure Scale
10-item parent-based scale assessing sleep problems (6 point Likert scale). Scores: Difficulty falling asleep (1-6); Quality of sleep (3-18); Functional outcome (6-36). Lower scores indicate higher problems with item. Open-ended items: Time to fall asleep (1 \[0-15 minutes\] to 5 \[\>1 hour\]); Total hours (numbers associated with hours of sleep).
Time frame: Baseline, 8 weeks, 28 weeks
Population: Randomized participants with a value at timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Sleep Measure Scale | Difficulty Falling Asleep: Baseline (n=48, n=49) | 3.4 units on a scale | Standard Deviation 1.91 |
| Atomoxetine | Sleep Measure Scale | Total Hours of Sleep: 28 Week (n=36, n=34) | 8.9 units on a scale | Standard Deviation 1.61 |
| Atomoxetine | Sleep Measure Scale | Time to Fall Asleep: Baseline (n=48, n=49) | 2.9 units on a scale | Standard Deviation 1.49 |
| Atomoxetine | Sleep Measure Scale | Quality of Sleep: Baseline (n=48, n=49) | 14.1 units on a scale | Standard Deviation 2.85 |
| Atomoxetine | Sleep Measure Scale | Difficulty Falling Asleep: 8 Week (n=43, n=46) | 3.6 units on a scale | Standard Deviation 1.8 |
| Atomoxetine | Sleep Measure Scale | Quality of Sleep: 8 Week (n=43, n=46) | 14.2 units on a scale | Standard Deviation 3.08 |
| Atomoxetine | Sleep Measure Scale | Time to Fall Asleep: 28 Week (n=35, n=35) | 3.1 units on a scale | Standard Deviation 1.49 |
| Atomoxetine | Sleep Measure Scale | Quality of Sleep: 28 Week (n=38, n=36) | 14.6 units on a scale | Standard Deviation 2.88 |
| Atomoxetine | Sleep Measure Scale | Difficulty Falling Asleep: 28 Week (n=38, n=36) | 3.2 units on a scale | Standard Deviation 1.76 |
| Atomoxetine | Sleep Measure Scale | Functional Outcome During Day:Baseline (n=48,n=49) | 29.6 units on a scale | Standard Deviation 4.69 |
| Atomoxetine | Sleep Measure Scale | Time to Fall Asleep: 8 Week (n=43, n=46) | 2.6 units on a scale | Standard Deviation 1.43 |
| Atomoxetine | Sleep Measure Scale | Functional Outcome During Day:8 Week (n=43,n=46) | 29.1 units on a scale | Standard Deviation 5.09 |
| Atomoxetine | Sleep Measure Scale | Total Hours of Sleep: Baseline (n=48, n=49) | 9.1 units on a scale | Standard Deviation 1.38 |
| Atomoxetine | Sleep Measure Scale | Functional Outcome During Day:28Week (n=38,n=36) | 27.8 units on a scale | Standard Deviation 6.38 |
| Atomoxetine | Sleep Measure Scale | Total Hours of Sleep: 8 Weeks (n=42, n=46) | 8.9 units on a scale | Standard Deviation 1.49 |
| Placebo | Sleep Measure Scale | Functional Outcome During Day:28Week (n=38,n=36) | 29.6 units on a scale | Standard Deviation 4.76 |
| Placebo | Sleep Measure Scale | Total Hours of Sleep: 8 Weeks (n=42, n=46) | 9.1 units on a scale | Standard Deviation 1.51 |
| Placebo | Sleep Measure Scale | Time to Fall Asleep: Baseline (n=48, n=49) | 2.8 units on a scale | Standard Deviation 1.41 |
| Placebo | Sleep Measure Scale | Time to Fall Asleep: 8 Week (n=43, n=46) | 3.0 units on a scale | Standard Deviation 1.34 |
| Placebo | Sleep Measure Scale | Time to Fall Asleep: 28 Week (n=35, n=35) | 2.6 units on a scale | Standard Deviation 1.14 |
| Placebo | Sleep Measure Scale | Difficulty Falling Asleep: Baseline (n=48, n=49) | 3.3 units on a scale | Standard Deviation 1.58 |
| Placebo | Sleep Measure Scale | Difficulty Falling Asleep: 8 Week (n=43, n=46) | 3.3 units on a scale | Standard Deviation 1.64 |
| Placebo | Sleep Measure Scale | Difficulty Falling Asleep: 28 Week (n=38, n=36) | 3.7 units on a scale | Standard Deviation 1.69 |
| Placebo | Sleep Measure Scale | Total Hours of Sleep: Baseline (n=48, n=49) | 9.3 units on a scale | Standard Deviation 1.46 |
| Placebo | Sleep Measure Scale | Total Hours of Sleep: 28 Week (n=36, n=34) | 9.2 units on a scale | Standard Deviation 1.12 |
| Placebo | Sleep Measure Scale | Quality of Sleep: Baseline (n=48, n=49) | 14.4 units on a scale | Standard Deviation 2.84 |
| Placebo | Sleep Measure Scale | Quality of Sleep: 8 Week (n=43, n=46) | 14.9 units on a scale | Standard Deviation 2.86 |
| Placebo | Sleep Measure Scale | Quality of Sleep: 28 Week (n=38, n=36) | 15.0 units on a scale | Standard Deviation 2.35 |
| Placebo | Sleep Measure Scale | Functional Outcome During Day:Baseline (n=48,n=49) | 30.0 units on a scale | Standard Deviation 4.07 |
| Placebo | Sleep Measure Scale | Functional Outcome During Day:8 Week (n=43,n=46) | 30.0 units on a scale | Standard Deviation 4.8 |